BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sprycel dasatinib regulatory update

The European Commission approved an MAA to extend the indication of Sprycel dasatinib from Bristol-Myers to include first-line treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >